Allergan board unanimously rebuffs latest acquisition offer from Valeant, Pershing Square
Allergan's board is unanimously rejecting the latest takeover bid from Valeant Pharmaceuticals, and the Botox maker says the offer isn't even worth talking about.
Allergan says a May 30 offer from the Canadian drugmaker and activist investor Bill Ackman's Pershing Square Capital Management still substantially undervalues Allergan Inc. and creates too much risk for shareholders. Allergan also says the deal doesn't offer enough value to warrant discussions between the companies.
That deal amounts to around $53 billion. It includes $72 in cash and a portion of Valeant Pharmaceuticals International Inc. stock for each Allergan share and was up from a previous bid that involved $58.30 in cash and the stock portion.
Ackman is a big Allergan shareholder. He has said he will move to replace most of Allergan's board.
Read more Business News
- Deadly crashKelowna
- No school TuesdayBC
- Rockets win pre-season openerSports
- US airstrikes accompany food dropsWorld
|QHR Technologies Inc||1.19||0.00|
|Anavex Life Sciences||0.25||+0.01|
|Copper Mountain Mining||2.93||+0.02|
|Sunrise Resources Ltd||0.025||0.00|
|Mission Ready Services||0.245||-0.005|
Apple has taught many entrepreneurs the importance of design, how to create buzz when introducing new products to the marketplace, how to pioneer new technology and the importance of superior quality....
Move over “big guys” there’s a new brokerage in town featuring local expertise, long standing experience and a fresh boutique approach. Kelowna, August 31 2014 – You may have...
There are several things to consider when deciding how much home to buy. 1. Draw up a budget including the new mortgage payments. While the rules used by most lenders require that the mortgage paym...